Avacta Group Q&A: Positive results from first set of COVID-19 test strips (LON:AVCT)

Avacta Group plc (LON:AVCT) Chief Executive Officer Alistair Smith caught up with DirectorsTalk for an exclusive interview to discuss progress of the COVID-19 antigen test strips, the next steps in development with Cytiva and how some of the Affimer reagents can prevent the virus from getting into human cells.

Q1: This morning you announced a positive progress update regarding the rapid COVID-19 antigen test development with Cytiva. Could you talk us through that update please?

A1: Just as a reminder, we are using Avacta Group’s Affimer reagents to develop a rapid test strip that intends to use saliva as the sample to detect the virus antigen. So, that’s a test that’s designed to tell you in a few minutes whether you’ve got the disease right now or not and not an antibody test that tells you whether you’ve had it for a while or in the past. So, that’s what we’re developing.

The announcement today was to update the market on positive results from the first set of test strips developed by Cytiva.

So, patients with COVID-19 show a range of concentration of the virus in their saliva and I’m pleased to say that the first attempt, which we announced this morning, the test strips are detecting these spike protein within that clinic development range.

Q2: So, what are the next steps in the development plan with Cytiva?

A2: This is a really good start, now our partners at Cytiva are working to refine and optimise all the different components of the test strips so we can detect the lowest possible concentration of the coronavirus spike protein in the samples. That’s important because it’s going to be a major factor in determining the clinical sensitivity of the test which is key obviously.

Once we’ve optimised the test strip then we’ll have a design that we can transfer to manufacturers who we’re putting in place at the moment. One of our biggest challenges right now is in compressing the normal diagnostic development timeline which could be 18 months or more and compressing that into a matter of weeks.

When we’ve put those manufacturing partners in place and we’ve agreed with them those development plans and timeline then we’ll be able to update the market more accurately.

Q3: Now, you also recently announced that some of the Affimer reagents that you’ve developed which block the interaction between the virus spike protein and a human cell receptor have now been shown to prevent infection of human cells in a model coronavirus system. Could you explain that please?

A3: So, as you said, some of the Affimer reagents that we generate for diagnostic purposes, which is our focus, also block the interaction between the virus spike protein and a receptor on human cells called ACE2. The binding of the coronavirus spike protein to ACE2 is the first step in the virus infecting human cells so in principal, if you can prevent that interaction from occurring you’ve got the potential for a treatment for COVID-19.

Last week, working with Professor David Bhella’s group at Glasgow University Centre for Virus Research, using a model for the coronavirus, Avacta Group showed that if you treat the virus with the Affimer reagents then the virus is prevented from getting into human cells.

So, that’s a really interesting finding and there’s numerous large pharmaceutical companies now investing heavily in developing these types of, what we call, neutralising therapies. We’re working hard to secure a partnership to develop potential Affimer therapies for COVID-19.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Avacta Group Plc

More articles like this

Avacta Group Plc

Avacta plc notice regarding publication error

Regarding a recent aggregated news article published earlier today, which has since been taken down, this was an error on the DirectorsTalk part linking to old news. This was nothing to do with Avacta Plc. The

Avacta Group Plc

Avacta inks radiopharma deal with POINT Biopharma

UK-based Avacta Group (AIM: AVCT) has entered into a license agreement with Canadian firm POINT Biopharma to provide access to Avacta’s pre|CISION technology for the development of tumor-activated radiopharmaceuticals.  The radiopharmaceutical market is expected to grow

Avacta Group Plc

Avacta signs new cancer therapy deal

Avacta Group, the developer of innovative cancer therapies, has entered into a license agreement with Point Biopharma to provide access to Avacta’s technology for the development of tumour-activated radiopharmaceuticals. Radiopharmaceutical therapy is now seen as a

Avacta Group Plc

Research looks to improve wastewater testing for COVID-19

Accurately identifying changes in community COVID-19 infections through wastewater surveillance is moving closer to reality. A new study, published in Environmental Science & Technology, identifies a method that not only detects the virus in wastewater samples but also

Avacta Group Plc

Hopes for clinical trial on humans of tumour targeting drug

Hopes for clinical trial of tumour targeting drug by Avacta. The company has filed an application for phase one testing, for its pre|CISION prodrug AVA6000. If approved, it will be tested on patients with metastatic solid tumours. The

Avacta Group Plc

BioSpace global roundup

U.K.-based Avacta Group announced significant progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good analytical

Avacta Group Plc

Talks could trigger COVID test rollout

Cambridge biotech Avacta Group is in discussions with commercial partners to establish a route to market for a CE marked BAMS COVID-19 test that can be deployed in hospitals in the UK and Europe. It is